President and Chief Executive Officer
Tagworks Pharmaceuticals
Ken Mills is the Chief Executive Officer and Director of Tagworks Pharmaceuticals. Tagworks Pharmaceuticals, is a precision oncology company using its proprietary Click-to-Release treatment platform to develop a new standard of care for patients suffering from solid tumors by targeting clinically validated tumor markers that so far have remained out of reach of current therapies. Its lead program, TGW101, is an antibody-drug conjugate (ADC) targeting TAG72, a non-internalizing protein found on the surface of many solid tumor cells. Tagworks is developing a pipeline of novel cancer treatments leveraging its Click-to-Release technology in a range of therapeutic modalities, including ADCs and targeted radionuclide therapies. The company is headquartered in the Netherlands with operations in the U.S.
Prior to his role at Tagworks, Ken has served as the founding President and Chief Executive Officer of REGENXBIO, Chief Financial Officer and Vice President of Business Development at Meso Scale Diagnostics, and Director of Business Development for IGEN International. Mr. Mills received an S.B. in chemistry from the Massachusetts Institute of Technology.